---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-266663"
form_type: "8-K"
ticker: "ALEC"
cik: "0001653087"
company_name: "Alector, Inc."
filed_at: "2021-09-07T23:59:59+00:00"
generated_at: "2026-06-29T05:33:07.700397+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Alector announces planned departure of President/COO and CMO; appoints interim CMO

## Summary
- Shehnaaz Suliman (President/COO) to step down; transition through Dec 31, 2021, then advisor.
- Robert Paul (CMO) steps down; will work part-time ($1,730/week) until Oct 31 health benefits, then advisor.
- Sam Jackson, SVP Clinical Sciences, appointed interim CMO effective Sept 7, 2021.
- Both executives will remain as advisors until end of 2021.
- Dr. Suliman joined 2019, Dr. Paul 2016; transitions are voluntary.

## SEC filing metadata
- accession: 0001193125-21-266663
- form_type: 8-K
- ticker: ALEC
- cik: 0001653087
- company_name: Alector, Inc.
- filed_at: 2021-09-07T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1653087/000119312521266663/0001193125-21-266663-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1653087/000119312521266663/d331079d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-266663
- JSON: https://secwatch.observer/filing/0001193125-21-266663.json
- Plain text: https://secwatch.observer/filing/0001193125-21-266663.txt

## Key facts
- Executive change
  Shehnaaz Suliman changed role as President and Chief Operating Officer at Alector, Inc..
  - Action: transition
  - Role: President and Chief Operating Officer
  source text: On September 7, 2021, Alector, LLC, a subsidiary of Alector, Inc. (collectively, the “Company”) entered into an agreement (the “Transition Agreement”) with Shehnaaz Suliman, the Company’s President and Chief Operating Officer, setting forth the terms of Dr. Suliman’s voluntary transition from the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1653087/000119312521266663/0001193125-21-266663-index.htm
- Executive change
  Robert Paul changed role as Chief Medical Officer at Alector, Inc..
  - Action: transition
  - Role: Chief Medical Officer
  source text: on September 7, 2021, the Company entered into a letter agreement (the “Letter Agreement”) with Robert Paul, the Company’s Chief Medical Officer, setting forth the terms of Dr. Paul’s voluntary transition from the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1653087/000119312521266663/0001193125-21-266663-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.